{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:24:27Z","timestamp":1789161867813,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA181491"],"award-info":[{"award-number":["R00CA181491"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA68485"],"award-info":[{"award-number":["P30CA68485"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K23CA204726"],"award-info":[{"award-number":["K23CA204726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0584-2","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T16:54:02Z","timestamp":1557248042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates"],"prefix":"10.1136","volume":"7","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-5974","authenticated-orcid":false,"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"issue":"3","key":"584_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov"},{"issue":"4","key":"584_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1078-0432.CCR-14-3175","volume":"22","author":"A Desrichard","year":"2016","unstructured":"Desrichard A, Snyder A, Chan TA. Cancer Neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22(4):807\u201312.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"584_CR3","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"MM Gubin","year":"2015","unstructured":"Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413\u201321.","journal-title":"J Clin Invest"},{"issue":"1","key":"584_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.smim.2015.11.002","volume":"28","author":"YC Lu","year":"2016","unstructured":"Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28(1):22\u20137.","journal-title":"Semin Immunol"},{"issue":"7","key":"584_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/dxw026","volume":"28","author":"YC Lu","year":"2016","unstructured":"Lu YC, Robbins PF. Targeting neoantigens for cancer immunotherapy. Int Immunol. 2016;28(7):365\u201370.","journal-title":"Int Immunol"},{"issue":"6280","key":"584_CR6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science."},{"issue":"1\u20132","key":"584_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1\u20132):48\u201361.","journal-title":"Cell."},{"issue":"23","key":"584_CR8","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"issue":"6257","key":"584_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Allen Van","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311.","journal-title":"Science."},{"issue":"2","key":"584_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.6004\/jnccn.2017.0016","volume":"15","author":"J Gong","year":"2017","unstructured":"Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal Cancer harboring a POLE mutation. J Natl Compr Cancer Netw. 2017;15(2):142\u20137.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"584_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","volume":"1","author":"BE Howitt","year":"2015","unstructured":"Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of Polymerase e-mutated and microsatellite-instable endometrial cancers with Neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319\u201323.","journal-title":"JAMA Oncol"},{"issue":"6","key":"584_CR12","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1172\/JCI84940","volume":"126","author":"JM Mehnert","year":"2016","unstructured":"Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6):2334\u201340.","journal-title":"J Clin Invest"},{"issue":"26","key":"584_CR13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"11","key":"584_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","volume":"4","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4(11):959\u201367.","journal-title":"Cancer Immunol Res"},{"issue":"6230","key":"584_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunologyMutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science."},{"issue":"1","key":"584_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome medicine. 2017;9(1):34.","journal-title":"Genome medicine"},{"issue":"9","key":"584_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"key":"584_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev.immunol.19.1.331","volume":"19","author":"W Reith","year":"2001","unstructured":"Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 2001;19:331\u201373.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"584_CR19","first-page":"1119","volume":"7","author":"JM Yavorski","year":"2017","unstructured":"Yavorski JM, Blanck G. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Molecular and clinical oncology. 2017;7(6):1119\u201321.","journal-title":"Molecular and clinical oncology"},{"issue":"5","key":"584_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov."},{"key":"584_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.gde.2013.12.005","volume":"24","author":"E Heitzer","year":"2014","unstructured":"Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev. 2014;24:107\u201313.","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"584_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal patterns of selection in Cancer and somatic tissues. Cell. 2017;171(5):1029\u201341 e21.","journal-title":"Cell."},{"issue":"1","key":"584_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1006\/scel.1993.1007","volume":"4","author":"A Townsend","year":"1993","unstructured":"Townsend A, Trowsdale J. The transporters associated with antigen presentation. Semin Cell Biol. 1993;4(1):53\u201361.","journal-title":"Semin Cell Biol"},{"issue":"379","key":"584_CR24","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"Whijae Roh","year":"2017","unstructured":"Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379).","journal-title":"Science Translational Medicine"},{"issue":"4","key":"584_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. 2017;171(4):934\u201349 e16.","journal-title":"Cell."},{"issue":"6349","key":"584_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science."},{"issue":"50","key":"584_CR27","doi-asserted-by":"publisher","first-page":"20007","DOI":"10.1073\/pnas.0710052104","volume":"104","author":"R Beroukhim","year":"2007","unstructured":"Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104(50):20007\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7283","key":"584_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899\u2013905.","journal-title":"Nature."},{"issue":"10","key":"584_CR29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/ng.238","volume":"40","author":"SA McCarroll","year":"2008","unstructured":"McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40(10):1166\u201374.","journal-title":"Nat Genet"},{"issue":"4","key":"584_CR30","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"23","key":"584_CR31","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310\u20136.","journal-title":"Bioinformatics."},{"issue":"4","key":"584_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/bioinformatics\/btp692","volume":"26","author":"B Li","year":"2010","unstructured":"Li B, Ruotti V, Stewart RM, Thomson JA, Dewey CN. RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics. 2010;26(4):493\u2013500.","journal-title":"Bioinformatics."},{"issue":"9","key":"584_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00262-017-2001-3","volume":"66","author":"AM Bjerregaard","year":"2017","unstructured":"Bjerregaard AM, Nielsen M, Hadrup SR, Szallasi Z, Eklund AC. MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol Immunother. 2017;66(9):1123\u201330.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"584_CR34","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"584_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","volume":"124","author":"M Rajasagi","year":"2014","unstructured":"Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453\u201362.","journal-title":"Blood."},{"issue":"1","key":"584_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/oxfordjournals.molbev.a026236","volume":"17","author":"Z Yang","year":"2000","unstructured":"Yang Z, Nielsen R. Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models. Mol Biol Evol. 2000;17(1):32\u201343.","journal-title":"Mol Biol Evol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0584-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:17Z","timestamp":1601055857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0584-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0584-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests relevant to this work. DBJ is on advisory boards for Array, BMS, Genoptix, Incyte, Merck, and has received research funding from BMS and Incyte. JMB receives consulting fees from Novartis and grant funding from Incyte and Genentech.\u00a0Luis A. Diaz (LAD) is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. LAD holds equity in PapGene, PGDx and Neophore. He is a paid consultant for PGDx and Phoremost. He is an uncompensated consultant for Merck. LAD is an inventor of multiple patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. These licenses and relationships are associated with equity or royalty payments to LAD. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. In addition, in the past 5 years, LAD has participated as a paid consultant for Merck and for one-time engagements with Caris, Lyndra, Genocea Biosciences, Illumina and Cell Design Labs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"123"}}